Mesalazina Doc

Mesalazine, the active ingredient in Mesalazina Doc, is a aminosalicylate presented as a rectal formulation for rectal use. It reduces inflammation in the colon and is used to treat ulcerative colitis and other inflammatory bowel disease in adult patients, helping to induce and maintain remission.

GNH USA supplies Mesalazina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU manufacturing standards and providing reliable global distribution.

Mesalazine is employed in the management of inflammatory bowel disease, acting directly on colonic inflammation.

- Ulcerative colitis: reduces mucosal inflammation and helps achieve remission. - Maintenance therapy in ulcerative colitis: sustains remission and prevents flare‑ups. - Inflammatory bowel disease (general): alleviates colonic lesions and associated symptoms.

Mesalazine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Abdominal pain or cramping - Diarrhea or loose stools - Nausea or mild vomiting - Headache - Flatulence or bloating - Rectal irritation or burning sensation

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Myocarditis or pericarditis - Acute pancreatitis - Blood dyscrasias such as neutropenia or agranulocytosis - Hepatotoxicity (elevated liver enzymes, hepatitis) - Interstitial nephritis or renal impairment

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor organ function.

- Monitor renal function: assess serum creatinine before and during treatment. - Assess hepatic function: periodic liver enzyme testing is recommended. - Evaluate for hypersensitivity: discontinue if rash, fever, or systemic allergic signs develop. - Use with caution in severe ulcerative colitis: consider alternative or adjunctive therapies. - Avoid in patients with known hypersensitivity to salicylates. - Store at room temperature: keep in original container, protect from moisture and light.

Mesalazine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Methotrexate: heightened toxicity and bone‑marrow suppression. - Live vaccines: possible reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression; monitor blood counts. - NSAIDs: may exacerbate renal impairment; assess renal function. - Diuretics: monitor electrolytes and renal function for potential imbalance.